Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
June 23 – COVID-19 pandemic – Washington reports their first case of the Lineage P.1 Gamma variant in an unvaccinated Clallam County resident who traveled out of the state. June 24 Surfside condominium building collapse – A 12-story condominium apartment building in Surfside, Florida partially collapses. At the official end of search on July 23, the death toll is 97, with one further person unaccounted for. A pedestrian bridge on Interstate 295 collapses in northeastern Washington, D.C., injuring five. Infrastructure policy of the Joe Biden administration: President Biden announces that he has reached a bipartisan infrastructure deal with Senators. Aftermath of the January 6 United States Capitol attack – Over 500 suspects have been arrested since the Capitol riot. U.S. Attorney General Merrick Garland announces that the first suspect is arrested for assaulting media during the events of January 6. The Appellate Division of the New York Supreme Court suspends former New York City Mayor Rudy Giuliani from practicing law over his false claims about the 2020 election. Microsoft unveils Windows 11, the latest generation of its computer operating system. The Federal Aviation Administration approves a request to rename McCarran International Airport in Las Vegas, currently the seventh-busiest airport by passenger traffic in the United States, to Harry Reid International Airport. June 25 Defending Stanley Cup champion Tampa Bay Lightning advance to the Stanley Cup Finals to face the Montreal Canadiens.
== Neem patent == In 1995, the European Patent Office (EPO) granted a patent on an anti-fungal product derived from the neem tree to the United States Department of Agriculture and W. R. Grace. The Indian government challenged the patent when it was granted, claiming that the process for which the patent had been granted had been in use in India for more than 2,000 years. In 2000, the EPO ruled in India's favour, but W. R. Grace appealed, claiming that prior art about the product had never been published in a scientific journal. On March 8, 2005, that appeal was lost and the EPO revoked the Neem patent.
The diagnosis of CSA syndrome is made when the presence of at least 5 central apnea events occur per hour. There are multiple mechanisms that drive the apnea events. In individuals with heart failure with Cheyne-Stokes respiration, the brain's respiratory control centers are imbalanced during sleep. This results in ventilatory instability, caused by chemoreceptors that are hyperresponsive to CO2 fluctuations in the blood, resulting in high respiratory drive that leads to apnea. Another common mechanism that causes CSA is the loss of the brain's wakefulness drive to breathe.
Sources: en.wikipedia.org
In November 2025, Valve announced a redesigned Steam Controller and Steam Machine and a new VR headset, Steam Frame. They were scheduled for release in early 2026, but were delayed by the RAM crisis. The second-generation Steam Controller was released on May 4. In June 2026, Valve released the Steam Machine, its first dedicated living room gaming PC since the original Steam Machines introduced in 2015. The company launched the device with a randomized reservation system because of limited production caused by global memory and storage shortages, with prices starting at $1,049 for the base model. In September 2026, around 12TB of data was extracted from Steam, including complete games, beta versions and prototypes dating between 2003 and 2013, from both Valve and other third-party developers. The anonymous person that disseminated the data claimed it was available without protection from older Steam servers used during that period, which Valve since transitioned from.
Calcium and bone disorders: Endocrinologists also treat conditions that affect calcium levels in the blood, such as hyperparathyroidism (high amounts of parathyroid hormone) and osteoporosis (weak bones). Sexual and reproductive disorders: Endocrinologists can also help diagnose and treat hormonal problems that affect sexual development and function, such as polycystic ovary syndrome (PCOS) and erectile dysfunction. Endocrine cancers: These are cancers that develop in the endocrine glands. Endocrinologists can help diagnose and treat these cancers.
=== Section Cyclopia === Cyclopia alpina A.L. Schutte Cyclopia falcata (Harv.) Kies (= Cyclopia subternata Vogel) Cyclopia galioides (Bergius) DC. Cyclopia genistoides (L.) Vent. Cyclopia intermedia E. Mey.
Sources: en.wikipedia.org
Calcium aluminate cements were patented in 1908 in France by Jules Bied for better resistance to sulfates. Also in 1908, Thomas Edison experimented with pre-cast concrete in houses in Union, N.J. In the US, after World War One, the long curing time of at least a month for Rosendale cement made it unpopular for constructing highways and bridges, and many states and construction firms turned to Portland cement. Because of the switch to Portland cement, by the end of the 1920s only one of the 15 Rosendale cement companies had survived. But in the early 1930s, builders discovered that, while Portland cement set faster, it was not as durable, especially for highways—to the point that some states stopped building highways and roads with cement. Bertrain H. Wait, an engineer whose company had helped construct the New York City's Catskill Aqueduct, was impressed with the durability of Rosendale cement, and came up with a blend of both Rosendale and Portland cements that had the good attributes of both. It was highly durable and had a much faster setting time. Wait convinced the New York Commissioner of Highways to construct an experimental section of highway near New Paltz, New York, using one sack of Rosendale to six sacks of Portland cement. It was a success, and for decades the Rosendale-Portland cement blend was used in concrete highway and concrete bridge construction. Cementitious materials have been used as a nuclear waste immobilizing matrix for more than a half-century.
Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of respiratory diseases affecting the interstitium (the tissue) and space around the alveoli (air sacs) of the lungs. It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues. It may occur when an injury to the lungs triggers an abnormal healing response. Ordinarily, the body generates just the right amount of tissue to repair damage, but in interstitial lung disease, the repair process is disrupted, and the tissue around the air sacs (alveoli) becomes scarred and thickened. This makes it more difficult for oxygen to pass into the bloodstream. The disease presents itself with the following symptoms: shortness of breath, nonproductive coughing, fatigue, and weight loss, which tend to develop slowly, over several months. While many forms are progressive and serious, some types of ILD remain mild or stable for extended periods, especially with early detection and appropriate treatment. The average rate of survival for someone with this disease is between three and five years. The term ILD is used to distinguish these diseases from obstructive airways diseases. There are specific types in children, known as children's interstitial lung diseases. The acronym ChILD is sometimes used for this group of diseases. In children, the pathophysiology involves a genetic component, exposure-related injury, autoimmune dysregulation, or all of the components.
The first substrate-level phosphorylation occurs after the conversion of 3-phosphoglyceraldehyde and Pi and NAD+ to 1,3-bisphosphoglycerate via glyceraldehyde 3-phosphate dehydrogenase. 1,3-bisphosphoglycerate is then dephosphorylated via phosphoglycerate kinase, producing 3-phosphoglycerate and ATP through a substrate-level phosphorylation. The second substrate-level phosphorylation occurs by dephosphorylating phosphoenolpyruvate, catalyzed by pyruvate kinase, producing pyruvate and ATP. During the preparatory phase, each 6-carbon glucose molecule is broken into two 3-carbon molecules. Thus, in glycolysis substrate-level phosphorylation produces 4 ATP molecules. However, the prior preparatory phase consumes 2 ATP molecules, so the net yield in glycolysis is 2 ATP molecules. 2 molecules of NADH are also produced and can be used in oxidative phosphorylation to generate more ATP.
==== Astrocytes and blood oxygen levels ==== The Sur lab has discovered novel and critical roles for astrocytes in brain function. By high resolution imaging in the intact visual cortex, they showed that astrocytes have tuned calcium responses to visual stimuli that are mediated importantly via glutamate transporters on astrocyte processes that surround synapses, and they influence local blood flow and hence the hemodynamic signals that underlie brain imaging methods such as fMRI. Role of astrocytes in information processing and plasticity Astrocytes are also activated by neuromodulators such as acetylcholine and norepinephrine, and Sur and coworkers showed that cholinergic inputs to cortex act via astrocytes to alter the strength of excitatory synapses and implement plasticity of neuronal responses. Furthermore, astrocyte GABA transporters regulate extrasynaptic GABA and influence population coding of visual information by V1 neurons. Astrocyte calcium signaling influences excitatory drive to inhibitory neurons, thereby enabling astrocytes to modulate excitatory-inhibitory balance in neuronal V1 circuits. Astrocytes and learning Glutamate transporters on astrocytes regulate developmental plasticity in visual cortex. Gene expression (of glutamate and GABA transporters) in cortical astrocytes is modulated by learning, and astrocytes thus crucially shape cortical neuronal activity underlying learned behavior.
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.